WET AMD
Clinical trials for WET AMD explained in plain language.
Never miss a new study
Get alerted when new WET AMD trials appear
Sign up with your email to follow new studies for WET AMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
One-Shot gene therapy could change wet AMD treatment
Disease control Recruiting nowThis study tests a new gene therapy called LX102 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment is given as a single injection under the retina and is compared to standard eye injections. The goal is to see if LX102 can i…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Innostellar Biotherapeutics Co.,Ltd • Aim: Disease control
Last updated May 17, 2026 06:19 UTC
-
One-shot gene therapy could cut eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of Ixo-vec gene therapy in 284 people with wet age-related macular degeneration (nAMD). The goal is to see if Ixo-vec can maintain or improve vision as well as standard aflibercept injections, but with fewer follow-up injections. Partic…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
One shot to save sight? gene therapy trial aims to end frequent eye injections for wet AMD
Disease control Recruiting nowThis phase 3 study tests a single injection of a gene therapy called Ixo-vec for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if this one-time treatment can maintain or improve vision as well as standard care (afliberc…
Matched conditions: WET AMD
Phase: PHASE3 • Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC